Insight, China's Pharmaceutical Industry

Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced it has received clinical approval from China’s...

Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026

Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a China-based blood products manufacturer, announced plans...

Company Deals

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

Fineline Cube May 13, 2026

Cellular Intelligence announced on May 11, 2026, that it has acquired global rights to Novo...

Others

Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development

Fineline Cube May 13, 2026

Porton Advanced Solutions and Dark Horse Consulting Group (“DHCG”) announced on May 12, 2026, the...

Company Drug

Servier’s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma

Fineline Cube May 13, 2026

Servier announced on May 12, 2026, that the U.S. Food and Drug Administration (FDA) has...

Company Drug

ImmuneOnco Receives NMPA Approval for IMM0306 Clinical Study in Primary Sjögren’s Syndrome, Expanding Dual-Target Bispecific Platform

Fineline Cube May 13, 2026

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced it has received clinical approval from China’s...

Others

Bayer Reports 4.1% Q1 Sales Growth to €13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition

Fineline Cube May 13, 2026

Bayer AG (ETR: BAYN) reported first-quarter 2026 group sales of €13.405 billion (USD 15.73 billion),...

Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Fineline Cube May 13, 2026

Boehringer Ingelheim (“BI”) and Immunitas Therapeutics announced on May 12, 2026, a global licensing agreement...

Company Medical Device

Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection

Fineline Cube May 13, 2026

Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced on May 12, 2026, that it has received...

Company Drug

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

Fineline Cube May 13, 2026

Alphamab Oncology (HKG: 9966) announced the initiation of a Phase II clinical study for its...

Company Drug

Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China

Fineline Cube May 13, 2026

Bio-Thera Solutions Ltd. (SHA: 688177) announced that its CD25-targeted antibody drug conjugate (ADC) BAT8013 has...

Company Drug

Sichuan Biokin’s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China

Fineline Cube May 13, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its bispecific antibody-drug conjugate (ADC) izalontamab...

Policy / Regulatory

Hong Kong to Launch FDA-Style Medical Products Regulation Center by Year-End, Creating Gateway for Chinese Innovative Drugs

Fineline Cube May 13, 2026

Hong Kong’s Centre for Medical Products Regulation (CMPR) is set to be established by the...

Company Drug

Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy

Fineline Cube May 13, 2026

Changchun GeneScience Pharmaceutical Co., Ltd. (SHE: 000661) announced it has received approval from China’s National...

Company

MacroGenics Sells GMP-Compliant API Manufacturing Business to Bora Pharmaceuticals for $122.5 Million

Fineline Cube May 13, 2026

MacroGenics, Inc. (NASDAQ: MGNX) announced an agreement to sell its active pharmaceutical ingredient (API) manufacturing...

Company Drug

Merus’ Bizengri Becomes First FDA-Approved Therapy for NRG1 Fusion-Positive Cholangiocarcinoma

Fineline Cube May 12, 2026

The U.S. Food and Drug Administration (FDA) granted approval to Merus N.V.’s Bizengri (zenocutuzumab-zbco) for...

Company Drug

Zai Lab Secures FDA Fast Track Designation for DLL3-Targeting ADC Zocilurtatug Pelitecan in Extrapulmonary NEC

Fineline Cube May 12, 2026

Zai Lab (NASDAQ: ZLAB, HKG: 9688) announced that the U.S. Food and Drug Administration (FDA)...

Company Deals

Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration

Fineline Cube May 12, 2026

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760), the globally leading medical device innovator, announced...

Company Drug

Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention

Fineline Cube May 12, 2026

Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a clinical trial...

Company Drug

Haisco Pharmaceutical’s Sishujing Seeks Postoperative Pain Indication, Expanding Peripheral Kappa Agonist Franchise

Fineline Cube May 12, 2026

Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China’s National Medical Products Administration (NMPA)...

Insight, China's Pharmaceutical Industry

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance

Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Sichuan Kelun-Biotech Receives NMPA Approval for ITGB6-Targeted ADC SKB105 in Advanced Solid Tumors Following Crescent Biopharma Licensing Deal

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Cellular Intelligence Acquires Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program, Plans AI-Driven Acceleration

Porton Advanced Solutions and Dark Horse Consulting Forge Strategic Alliance to Accelerate Global Cell and Gene Therapy Development

Servier’s B7-H4 ADC Emiltatug Ledadotin Receives FDA Breakthrough Therapy Designation for Advanced Adenoid Cystic Carcinoma

ImmuneOnco Receives NMPA Approval for IMM0306 Clinical Study in Primary Sjögren’s Syndrome, Expanding Dual-Target Bispecific Platform

Bayer Reports 4.1% Q1 Sales Growth to €13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China

Sichuan Biokin’s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China

Hong Kong to Launch FDA-Style Medical Products Regulation Center by Year-End, Creating Gateway for Chinese Innovative Drugs

Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy

MacroGenics Sells GMP-Compliant API Manufacturing Business to Bora Pharmaceuticals for $122.5 Million

Merus’ Bizengri Becomes First FDA-Approved Therapy for NRG1 Fusion-Positive Cholangiocarcinoma

Zai Lab Secures FDA Fast Track Designation for DLL3-Targeting ADC Zocilurtatug Pelitecan in Extrapulmonary NEC

Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration

Ribo Life Science Files EMA Application for Vortosiran Phase IIb Study in Venous Thromboembolism Prevention

Haisco Pharmaceutical’s Sishujing Seeks Postoperative Pain Indication, Expanding Peripheral Kappa Agonist Franchise

You Missed

China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion

Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend